These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24372322)

  • 1. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases.
    Khoury T; Karabakhtsian RG; Mattson D; Yan L; Syriac S; Habib F; Liu S; Desouki MM
    Histopathology; 2014 Jun; 64(7):981-93. PubMed ID: 24372322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
    Chivukula M; Haynik DM; Brufsky A; Carter G; Dabbs DJ
    Am J Surg Pathol; 2008 Nov; 32(11):1721-6. PubMed ID: 18769331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.
    Chen YY; Hwang ES; Roy R; DeVries S; Anderson J; Wa C; Fitzgibbons PL; Jacobs TW; MacGrogan G; Peterse H; Vincent-Salomon A; Tokuyasu T; Schnitt SJ; Waldman FM
    Am J Surg Pathol; 2009 Nov; 33(11):1683-94. PubMed ID: 19701073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis.
    Carder PJ; Shaaban A; Alizadeh Y; Kumarasuwamy V; Liston JC; Sharma N
    Histopathology; 2010 Sep; 57(3):472-8. PubMed ID: 20727019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ.
    Masannat YA; Husain E; Roylance R; Heys SD; Carder PJ; Ali H; Maurice Y; Pinder SE; Sawyer E; Shaaban AM
    Breast; 2018 Apr; 38():120-124. PubMed ID: 29310036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.
    De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA
    Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management.
    Flanagan MR; Rendi MH; Calhoun KE; Anderson BO; Javid SH
    Ann Surg Oncol; 2015 Dec; 22(13):4263-9. PubMed ID: 25893410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the management of pleomorphic lobular carcinoma in situ of the breast.
    Masannat YA; Bains SK; Pinder SE; Purushotham AD
    Breast; 2013 Apr; 22(2):194-196. PubMed ID: 23357705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.
    Sneige N; Wang J; Baker BA; Krishnamurthy S; Middleton LP
    Mod Pathol; 2002 Oct; 15(10):1044-50. PubMed ID: 12379750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.
    Manucha V; Khilko N; Reilly K; Zhang X
    Int J Clin Exp Pathol; 2011 Jan; 4(2):200-5. PubMed ID: 21326816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.
    Reis-Filho JS; Simpson PT; Jones C; Steele D; Mackay A; Iravani M; Fenwick K; Valgeirsson H; Lambros M; Ashworth A; Palacios J; Schmitt F; Lakhani SR
    J Pathol; 2005 Sep; 207(1):1-13. PubMed ID: 15957152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology.
    Lishman SC; Lakhani SR
    Histopathology; 1999 Sep; 35(3):195-200. PubMed ID: 10469210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
    Fowble B; Hanlon AL; Patchefsky A; Freedman G; Hoffman JP; Sigurdson ER; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):105-15. PubMed ID: 9747827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast.
    Desai AA; Jimenez RE; Hoskin TL; Day CN; Boughey JC; Hieken TJ
    Ann Surg Oncol; 2018 Oct; 25(10):3064-3068. PubMed ID: 29947004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.